Drug Profile
Research programme: soluble guanylate cyclase stimulants - Bayer
Alternative Names: BAY 41-2272; BAY 54-6544Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Bayer
- Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis
- Discontinued Heart failure; Hypertension
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Atherosclerosis in Germany (PO)
- 21 Jun 2019 Pharmacodynamics data from a preclinical studies in the Hypertension presented at the 29th European Meeting on Hypertension and Cardiovascular Protection (ESH-2019)
- 27 Aug 2018 Preclinical data for Atherosclerosis presented at the Annual Congress of the European Society of Cardiology (ESC Congress-2018)